Search results

China's National Development and Reform Commission and the State Administration for Industry and Commerce have issued a swathe of new rules on price and monopoly related abuses, which will come into effect on 1 February 2011. These long-awaited rules will guide...

Two of our recent briefings have explained the mechanics of China's new national review process, under which acquisitions of Chinese assets in certain industries may be reviewed and rejected on national security grounds. This new process was announced only a day...

"Foreign investors considering M&A activities in China may soon be subject to a security review system in addition to the existing antitrust review mechanism. With a view to protecting national security and preserving social and economic stability,...

China's Ministry of Commerce has released further details of the application and review procedures for the country's new national security review system for foreign M&A involving Chinese enterprises. In this briefing, our lawyers summarise the interim provisions...

In August 2011, China issued new provisions for its national security review system. These provisions cover procedure and reflect MOFCOM's latest instructions on the process and timeline for submitting applications for national security review, and should...

In this edition, we focus on antitrust issues, consider some of the challenges facing companies, and examine the enforcement trends in China. We also include three industry insight articles and two further articles on key developments in the regulatory...

In this edition, we have included two articles in our Industry Insights section and five on what we see as key developments in the regulatory environment. We also include a link to a comprehensive round up of regulatory changes at the end of this bulletin.

In this edition, we focus on off-label drug use and promotion, and provide a comparative analysis of China's legal regime with other jurisdictions in Europe and the US. In addition to our lead article, we have included two further legal updates on Good...

Selected regulatory changes April – June 2011 (English & Chinese)

In the first of two articles on the impact on pharmaceutical companies of China's antitrust regime, we focus on the changing shape of merger control review.